|
|
Investigation of the biomechanics of blue-light cross-linking on rabbit scleral tissue with different concentrations of riboflavin |
ZOU Ying,ZHANG Miao,ZHANG Fengju |
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Lab, Beijing 100730, China |
|
|
Abstract Objective This study had two objectives: To evaluate the efficiency of collagen cross-linking (CXL) in rabbit sclera induced by different concentrations of riboflavin and blue light.To find the optimal concentration of riboflavin in scleral cross-linking. Methods In this experimental study, scleral stress-strain measurementswere performed to evaluate the biomechanical efficiency of collagen cross-linking using riboflavin and blue light (460 nm). Ten New Zealand rabbits were randomly divided into Group Ⅰ and Ⅱ. In Group Ⅰ, a 0.1% riboflavin solution was used for the CXL induced by blue light. In Group Ⅱ, a 0.5% riboflavin solution was used. In each group, the right eye was defined as the experimental eye and the left eye was the control. Biomechanical measurements of scleral strips were performed 2 months after CXL using a microcomputer-controlled biomaterial testing device. The focus was on Young′s modulus calculated as σ=Aexp(B×ε) and maximum stress. The data were analyzed by paired sample t-test and two independent sample t-test. Results Scleral specimens from both groups exhibited nonlinear stress-strain behavior with an initially low Young′s modulus that increased gradually under higher stress. It was derived using the equation σ=Aexp(B×ε). The Young′s modulus (Group Ⅰ: t=19.78, P<0.01; Group Ⅱ: t=7.82, P<0.01) and maximum stress (Group Ⅰ: t=4.90, P<0.05; Group Ⅱ: t=4.30, P<0.05) of the sclera increased after CXL. In addition, the scleral strips in Group Ⅰ were stiffer than in Group Ⅱ (Young′s modulus: t=2.52, P<0.05; Maximum stress: t=3.03, P<0.05). Conclusion CXL induced by riboflavin/blue light can significantly enhance the biomechanical strength of rabbit sclera. The 0.1% riboflavin solution had significantly better biomechanical behavior than the 0.5% riboflavin in CXL.
|
Received: 04 August 2016
|
Fund: National Natural Science Foundation of China(81070763, 81570877); Key Project of Science and Technology Program of Beijing Municipal Education Commission(KZ20130025027); Beijing Health System High Level Health Technology Talent Fund (2013-2-023). |
Corresponding Authors:
ZHANG Fengju, Email: wxw93@hotmail.com
|
|
|
|
[1] |
Wollensak G, Spoerl E. Collagen crosslinking of human and porcine sclera[J]. J Cataract Refract Surg,2004,30(3):689-695. DOI:10.1016/j.jcrs.2003.11.032.
|
[2] |
Wollensak G, Iomdina E, Dittert DD, et al. Cross-linking of scleral collagen in the rabbit using riboflavin and UVA[J]. Acta Ophthalmol Scand,2005,83(4):477-482. DOI:10.1111/j.1600-0420. 2005.00447.x.
|
[3] |
Wollensak G, Iomdina E. Long-term biomechanical properties of rabbit sclera after collagen crosslinking using riboflavin and ultraviolet A (UVA)[J]. Acta Ophthalmol,2009,87(2):193-198. DOI:10.1111/j.1755-3768.2008.01229.x.
|
[4] |
Wang M, Zhang F, Liu K, et al. Safety evaluation of rabbit eyes on scleral collagen cross-linking by riboflavin and ultraviolet A[J]. Clin Exp Ophthalmol,2015,43(2):156-163. DOI:10.1111/ceo. 12392.
|
[5] |
Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin cross-linking of the cornea[J]. Cornea,2007,26(4):385-389. DOI: 10.1097/ICO.0b013e3180334f78.
|
[6] |
张淼,张丰菊. 胶原交联加强巩膜组织的研究进展[J]. 中华眼视光学与视觉科学杂志,2015,17(8):510-512. DOI:10.3760/cma.j.issn.1674-845X.2015.08.016.
|
[7] |
赵旭,王萌萌,张丰菊. 紫外线A-核黄素交联加固角巩膜安全性的研究进展[J]. 中华眼科杂志,2013,49(2):189-192. DOI:10.3760/ cma.j.issn.0412-4081.2013.02.023.
|
[8] |
张学敏,赵旭,张丰菊,等. 核黄素在巩膜组织内渗透性的实验研究[J]. 中华眼科杂志,2015,51(6):450-454. DOI:10.3760/cma.j.issn.0412-4081.2015.06.013.
|
[9] |
Iseli HP, Spoerl E, Wiedemann P, et al. Efficacy and safety of blue-light scleral cross-linking[J]. J Refract Surg,2008,24(7):S752-755.
|
[10] |
瞿佳,周翔天. 提升近视防治研究水平的难点与要点[J]. 中华医学杂志,2014,94(17):1281-1283. DOI:10.3760/cma.j.issn.0376-2491. 2014.17.001.
|
[11] |
Curtin BJ, Iwamoto T, Renaldo DP. Normal and staphylomatous sclera of high myopia. An electron microscopic study[J]. Arch Ophthalmol,1979,97(5):912-915.
|
[12] |
McBrien NA, Gentle A. Role of the sclera in the development and pathological complications of myopia[J]. Prog Retin Eye Res, 2003,22(3):307-338.
|
[13] |
刘修铎,吕嘉华,褚仁远. 后巩膜加固术治疗高度近视眼的远期临床疗效观察[J]. 中华眼科杂志,2011,47(6):527-530. DOI:10.3760/ cma.j.issn.0412-4081.2011.06.010.
|
[14] |
Schumacher S, Mrochen M, Wernli J, et al. Optimization model for UV-riboflavin corneal cross-linking[J]. Invest Ophthalmol Vis Sci,2012,53(2):762-769. DOI:10.1167/iovs.11-8059.
|
[15] |
Watson PG, Young RD. Scleral structure, organisation and disease. A review[J]. Exp Eye Res,2004,78(3):609-623. DOI:10.1016/S0014-4835(03)00212-4.
|
[16] |
Geraghty B, Jones SW, Rama P, et al. Age-related variations in the biomechanical properties of human sclera[J]. J Mech Behav Biomed Mater,2012,16:181-191. DOI:10.1016/j.jmbbm.2012.10.011.
|
[17] |
Wang M, Zhang F, Qian X, et al. Regional Biomechanical properties of human sclera after cross-linking by riboflavin/ ultraviolet A[J]. J Refract Surg,2012,28(10):723-728. DOI:10.3928/ 1081597X-20120921-08.
|
[18] |
Kymionis GD, Portaliou DM, Diakonis VF, et al. Corneal collagen cross-linking with riboflavin and ultraviolet-A irradiation in patients with thin corneas[J]. Am J Ophthalmol,2012,153(1):24-28. DOI:10.1016/j.ajo.2011.05.036.
|
[19] |
Bottós KM, Dreyfuss JL, Regatieri CV, et al. Immunofluorescence confocal microscopy of porcine corneas following collagen cross-linking treatment with riboflavin and ultraviolet A[J]. J Refract Surg,2008,24(7):S715-719.
|
[20] |
Nicoli S, Ferrari G, Quarta M, et al. Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability[J]. Mol Vis,2009,15:259-266.
|
[21] |
Molokhia SA, Jeong EK, Higuchi WI, et al. Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging[J]. Int J Pharm,2007,335(1-2):46-53. DOI:10.1016/j.ijpharm.2006.11.001.
|
|
|
|